Back to search results

CUSP2CT Project Trial for Cancer Clinical Trial Access

This study, called the CUSP2CT Project Trial, aims to improve how people from underrepresented groups, especially racial and ethnic minorities, are referred to and enroll in cancer clinical trials at Ohio State University. Clinical trials are important for finding better ways to prevent, detect, and treat cancer, but not everyone participates equally. This trial will first look at current referral patterns and then put into place new activities like educational sessions and discussions to help more people join trials. The main goal is to see if these efforts increase the number of referrals and enrollments of minorities into cancer clinical trials over a 24-month period. This study is for people of all ages and genders within specific counties and healthcare systems connected to OSUCCC.

Study design
This interventional study plans to enroll 208 participants. It uses a stepped wedge design, meaning different groups will receive the intervention at different times.
What's involved
Participants may engage in educational activities, discussions, interviews, and data reviews. The study measures changes over 24 months.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes from baseline up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06314672

Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial

Recruiting
NAAll AgesInterventionalHealth services
Ohio State University Comprehensive Cancer Center
~208 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:AccrualDiscussionEducational ActivityInterviewReviewSurvey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in referral rate to clinical trials (CTs) (short-term outcomes)
Measured over Baseline to 24 months
+4 more outcomes measured

Conditions

Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Electra D Paskett, PhD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center

Who to contact

The Ohio State Comprehensive Cancer Center
[email protected]
800-293-5066
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Phase I: 9 counties in the OSUCCC catchment area
Phase II: Patients, providers, and hospital systems/referral centers that directly addresses challenges identified in Phase I
Phase II: The project will involve the OSUCCC, the OSU James Cancer Network sites and the Columbus and Dayton NCORP sites

What this trial measures

  • Change in referral rate to clinical trials (CTs) (short-term outcomes)Baseline to 24 months

    Calculate change in clinical trial referrals

  • Change in accrual of minorities to CTs (short-term outcomes)Baseline to 24 months

    Calculate the change in clinical trial minority enrollments

  • CT accrual and retention due to patient navigation (short-term outcomes)Baseline to 24 months

    Calculate accrual and retention rates

  • Identification of program gaps in trial accrual (long-term outcomes)Up to 24 months

    Define gaps in trial accrual

  • Uptake of program in other clinics (long-germ outcomes)Up to 24 months

    Calculate the number of clinics who adapt program